Trial Profile

Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO).

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allopurinol (Primary)
Indications Gout; Hyperuricaemia
Focus Adverse reactions
Acronyms LASSO

Most Recent Events

17 Jun 2014 Biomarkers information updated
29 Oct 2013 Results were presented at the Annual Meeting of the American College of Rheumatology in October 2013.
28 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com